10-K/A Filing

Xenetic Biosciences, Inc. CIK: 1534525 FY 2013

Filing Information

Form Type	10-K/A
Accession Number	`0001193125-14-172830`
Period End Date	20131231
Filing Date	20140430
Fiscal Year	2013
Fiscal Period	FY
XBRL Instance	xbio-20131231.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 62 Income Statement 34 Cash Flow Statement 44 Stockholders Equity 14 Comprehensive Income 2

Balance Sheet 62 line items

Line Item	Tag	Value	Unit	Period
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	215.46M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	215.46M	shares	Point-in-time
Cash	`Cash`	$11.14M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	130.52M	shares	Point-in-time
Cash	`Cash`	$4.84M	USD	Point-in-time
Cash	`Cash`	$17.12M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	130.58M	shares	Point-in-time
Restricted cash	`RestrictedCashAndCashEquivalentsAtCarryingValue`	$66.00K	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	119.89M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	119.83M	shares	Point-in-time
Accounts receivable	`AccountsReceivableGrossCurrent`	$130.26K	USD	Point-in-time
Accounts receivable	`AccountsReceivableGrossCurrent`	-	USD	Point-in-time
Other receivables	`AccountsAndOtherReceivablesNetCurrent`	$256.01K	USD	Point-in-time
Other receivables	`AccountsAndOtherReceivablesNetCurrent`	$81.93K	USD	Point-in-time
Prepaid expenses and other	`PrepaidExpenseAndOtherAssetsCurrent`	$195.91K	USD	Point-in-time
Prepaid expenses and other	`PrepaidExpenseAndOtherAssetsCurrent`	$168.31K	USD	Point-in-time
Total current assets	`AssetsCurrent`	$11.54M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$5.33M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$152.60K	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$122.08K	USD	Point-in-time
Goodwill	`Goodwill`	-	USD	Point-in-time
Goodwill	`Goodwill`	$3.59M	USD	Point-in-time
Goodwill	`Goodwill`	$3.67M	USD	Point-in-time
Indefinite-lived intangible assets	`IndefiniteLivedIntangibleAssetsExcludingGoodwill`	$10.32M	USD	Point-in-time
Indefinite-lived intangible assets	`IndefiniteLivedIntangibleAssetsExcludingGoodwill`	$10.11M	USD	Point-in-time
Total assets	`Assets`	$19.47M	USD	Point-in-time
Total assets	`Assets`	$25.37M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$942.16K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$119.67K	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$456.74K	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$1.83M	USD	Point-in-time
Accrued payroll taxes	`AccruedPayrollTaxesCurrent`	$86.60K	USD	Point-in-time
Accrued payroll taxes	`AccruedPayrollTaxesCurrent`	$84.60K	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$55.27K	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$53.66K	USD	Point-in-time
Loans due to related parties	`DueToRelatedPartiesCurrent`	$681.12K	USD	Point-in-time
Loans due to related parties	`DueToRelatedPartiesCurrent`	$682.99K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$3.59M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.40M	USD	Point-in-time
Deferred tax liability	`DeferredTaxLiabilitiesNoncurrent`	$3.19M	USD	Point-in-time
Deferred tax liability	`DeferredTaxLiabilitiesNoncurrent`	$3.26M	USD	Point-in-time
Total liabilities	`Liabilities`	$6.85M	USD	Point-in-time
Total liabilities	`Liabilities`	$4.59M	USD	Point-in-time
Commitments and contingent liabilities (Note 9)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingent liabilities (Note 9)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Common stock, $0.01 par value; 215,456,000 shares authorized as of December 31, 2013 and 2012; 130,575,516 and 130,520,137 shares issued as of December 31, 2013 and 2012; 119,887,322 and 119,831,943 shares outstanding as of December 31, 2013 and 2012 respectively	`CommonStockValue`	$1.31M	USD	Point-in-time
Common stock, $0.01 par value; 215,456,000 shares authorized as of December 31, 2013 and 2012; 130,575,516 and 130,520,137 shares issued as of December 31, 2013 and 2012; 119,887,322 and 119,831,943 shares outstanding as of December 31, 2013 and 2012 respectively	`CommonStockValue`	$1.31M	USD	Point-in-time
Additional paid in capital	`AdditionalPaidInCapital`	$73.57M	USD	Point-in-time
Additional paid in capital	`AdditionalPaidInCapital`	$74.00M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-49.73M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-58.31M	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$915.60K	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$900.25K	USD	Point-in-time
Treasury stock	`TreasuryStockValue`	$5.28M	USD	Point-in-time
Treasury stock	`TreasuryStockValue`	$5.28M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$12.62M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$20.78M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$14.80M	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$19.47M	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$25.37M	USD	Point-in-time

Income Statement 34 line items

Line Item	Tag	Value	Unit	Period
Revenue	`Revenues`	$1.00M	USD	Annual
Revenue	`Revenues`	$293.60K	USD	Annual
Cost of revenue	`CostOfRevenue`	$44.84K	USD	Annual
Gross profit	`GrossProfit`	$248.76K	USD	Annual
Gross profit	`GrossProfit`	$1.00M	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$1.94M	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$3.06M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$3.56M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$6.55M	USD	Annual
Impairment of In-Process Research and Development	`ResearchAndDevelopmentInProcess`	$1.09M	USD	Annual
Total operating costs and expenses	`OperatingExpenses`	$9.61M	USD	Annual
Total operating costs and expenses	`OperatingExpenses`	$6.59M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-8.61M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-6.34M	USD	Annual
Interest income	`InvestmentIncomeInterest`	$34.85K	USD	Annual
Interest income	`InvestmentIncomeInterest`	$67.67K	USD	Annual
Interest expense	`InterestExpense`	$51.74K	USD	Annual
Interest expense	`InterestExpense`	$632.00	USD	Annual
Total other income (expense)	`OtherNonoperatingIncomeExpense`	$15.94K	USD	Annual
Total other income (expense)	`OtherNonoperatingIncomeExpense`	$34.22K	USD	Annual
Loss before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-8.58M	USD	Annual
Loss before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-6.33M	USD	Annual
Income tax	`IncomeTaxExpenseBenefit`	-	USD	Annual
Income tax	`IncomeTaxExpenseBenefit`	-	USD	Annual
Net loss	`ProfitLoss`	$-6.33M	USD	Annual
Net loss	`ProfitLoss`	$-8.58M	USD	Annual
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$1.17M	USD	Annual
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-15.34K	USD	Annual
Total comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-5.16M	USD	Annual
Total comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-8.59M	USD	Annual
Net loss per share of common stock, basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.05	USD	Annual
Net loss per share of common stock, basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.07	USD	Annual
Weighted-average shares of common stock outstanding, basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	119.83M	shares	Annual
Weighted-average shares of common stock outstanding, basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	119.84M	shares	Annual

Cash Flow Statement 44 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-6.33M	USD	Annual
Net loss	`ProfitLoss`	$-8.58M	USD	Annual
Depreciation	`Depreciation`	$104.62K	USD	Annual
Depreciation	`Depreciation`	$52.03K	USD	Annual
Share-based compensation	`ShareBasedCompensation`	$339.78K	USD	Annual
Share-based compensation	`ShareBasedCompensation`	$431.50K	USD	Annual
Non-cash impairment of acquired In-Process Research and Development	`ResearchAndDevelopmentInProcess`	$1.09M	USD	Annual
Non-cash interest income	`OtherNoncashIncome`	$577.00	USD	Annual
Non-cash interest expense	`OtherNoncashExpense`	$51.74K	USD	Annual
Foreign currency translation	`ForeignCurrencyTransactionGainLossBeforeTax`	$14.96K	USD	Annual
Foreign currency translation	`ForeignCurrencyTransactionGainLossBeforeTax`	$42.16K	USD	Annual
Accounts receivable, prepayments and other receivables	`IncreaseDecreaseInAccountsAndOtherReceivables`	$31.70K	USD	Annual
Accounts receivable, prepayments and other receivables	`IncreaseDecreaseInAccountsAndOtherReceivables`	$7.52K	USD	Annual
Accounts payable and accrued expenses	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-1.44M	USD	Annual
Accounts payable and accrued expenses	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$2.07M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-6.05M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-6.26M	USD	Annual
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$130.08K	USD	Annual
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$78.63K	USD	Annual
Sales of property and equipment	`ProceedsFromSaleOfPropertyPlantAndEquipment`	$37.85K	USD	Annual
Overdraft acquired with SymbioTec GmbH	`CashAcquiredFromAcquisition`	$-349.00	USD	Annual
Change in restricted cash	`IncreaseDecreaseInRestrictedCash`	$66.00K	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-92.59K	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-144.63K	USD	Annual
Proceeds from issuance of common stock	`ProceedsFromIssuanceOfCommonStock`	$421.16K	USD	Annual
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$709.00	USD	Annual
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$2.09K	USD	Annual
Employee participation in JSOP	`ProceedsFromEmployeesForIssuanceOfCommonStockToEmployeeBenefitTrust`	$61.75K	USD	Annual
Stock issuance costs	`PaymentsOfStockIssuanceCosts`	$80.77K	USD	Annual
Payments on loan from related party	`RepaymentsOfRelatedPartyDebt`	$706.20K	USD	Annual
Net cash provided by (used in) financing activities	`NetCashProvidedByUsedInFinancingActivities`	$2.09K	USD	Annual
Net cash provided by (used in) financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-303.35K	USD	Annual
Effect of exchange rate change on cash and cash equivalents	`EffectOfExchangeRateOnCashAndCashEquivalents`	$677.88K	USD	Annual
Effect of exchange rate change on cash and cash equivalents	`EffectOfExchangeRateOnCashAndCashEquivalents`	$-102.82K	USD	Annual
Net decrease in cash and cash equivalents, excluding restricted cash	`CashPeriodIncreaseDecrease`	$-5.98M	USD	Annual
Net decrease in cash and cash equivalents, excluding restricted cash	`CashPeriodIncreaseDecrease`	$-6.30M	USD	Annual
Cash and cash equivalents at beginning of year	`Cash`	$11.14M	USD	Point-in-time
Cash and cash equivalents at beginning of year	`Cash`	$4.84M	USD	Point-in-time
Cash and cash equivalents at beginning of year	`Cash`	$17.12M	USD	Point-in-time
Cash and cash equivalents at end of year	`Cash`	$11.14M	USD	Point-in-time
Cash and cash equivalents at end of year	`Cash`	$4.84M	USD	Point-in-time
Cash and cash equivalents at end of year	`Cash`	$17.12M	USD	Point-in-time
Issuance of common stock in connection with SymbioTec GmbH acquisition	`IssuanceOfCommonStockInConnectionWithBusinessCombination`	$9.34M	USD	Annual
Loan to JSOP trustees	`IssuanceOfCommonStockToEmployeeBenefitTrustFromTreasuryStockViaLoanToEmployeeBenefitTrust`	$-4.69M	USD	Annual

Stockholders Equity 14 line items

Line Item	Tag	Value	Unit	Period
Beginning Balance	`StockholdersEquity`	$12.62M	USD	Point-in-time
Beginning Balance	`StockholdersEquity`	$20.78M	USD	Point-in-time
Beginning Balance	`StockholdersEquity`	$14.80M	USD	Point-in-time
Exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$2.09K	USD	Annual
Exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$709.00	USD	Annual
Share-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$431.50K	USD	Annual
Share-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$339.78K	USD	Annual
Net loss	`ProfitLoss`	$-6.33M	USD	Annual
Net loss	`ProfitLoss`	$-8.58M	USD	Annual
Foreign currency translation	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$1.17M	USD	Annual
Foreign currency translation	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-15.34K	USD	Annual
Ending Balance	`StockholdersEquity`	$12.62M	USD	Point-in-time
Ending Balance	`StockholdersEquity`	$20.78M	USD	Point-in-time
Ending Balance	`StockholdersEquity`	$14.80M	USD	Point-in-time

Comprehensive Income 2 line items

Line Item	Tag	Value	Unit	Period
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.